CJC-1295 / Ipamorelin Blend (no DAC) (Research Overview)
This product is a blend of two separate peptides: CJC-1295 without the drug affinity complex (DAC), a modified analogue of growth hormone-releasing hormone fragment 1-29, and ipamorelin, a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classed as a growth hormone secretagogue. It is not the same material as CJC-1295 with DAC, which is a separate product.
Mechanism of Action
The two components act at different G protein-coupled receptors. Growth hormone-releasing hormone (GHRH) analogues engage the GHRH receptor, which signals through cAMP, and the neuroendocrine control of growth hormone involves interplay between GHRH and somatostatin neurons. Reviews describe the receptor, its splice variants and its signalling pathways.
Ipamorelin was described in 1998 as a pentapeptide derived from a series of compounds related to growth hormone-releasing peptide (GHRP)-1, and pharmacological profiling with receptor antagonists indicated that it acts through a GHRP-like receptor. That receptor, the growth hormone secretagogue receptor, was cloned in 1996, and an endogenous acylated peptide ligand, ghrelin, was identified in 1999.
Research Areas
Receptor pharmacology: GHRH receptor agonists and growth hormone secretagogue receptor agonists are characterized in separate cell-based and animal systems, where potency and receptor selectivity are compared.
Neuroendocrine background: reviews of growth hormone regulation describe the hypothalamic and pituitary circuitry involved in the two receptor pathways.
Component identity: because the two peptides have distinct structures and receptors, studies of either one individually (see the CJC-1295 and Ipamorelin research overviews) are the primary literature for each component.
Findings from published studies do not establish safety or efficacy for any indication and should not be interpreted as medical claims.
Specification summary
CJC-1295 / Ipamorelin Blend (no DAC)
Stated purity ≥99%. For laboratory research use only.
Related materials
References
- Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025;26(3):343-352. PMID 39934495 · DOI
- Bertherat J, Bluet-Pajot MT, Epelbaum J. Neuroendocrine regulation of growth hormone. Eur J Endocrinol. 1995;132(1):12-24. PMID 7850005 · DOI
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822 · DOI
- Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-7. PMID 8688086 · DOI
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60. PMID 10604470 · DOI
Cited literature is provided for scientific context only and does not describe or endorse any use of these products.
For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.